USA The Company anticipates that patient enrollment and treatment will escalate rapidly with the increased momentum as it launches additional clinical study sites, as UHN has now treated its second patient.
Shawn Shirazi, Ph.D., CEO - Drug Division, Theralase stated that, "I'm delighted that a high-quality organization such as LHSC has elected to join the Theralase team as the third Canadian study site that can enroll and treat patients with NMIBC, who are BCG-Unresponsive. We are working towards onboarding the rest of the Canadian study sites for Study II by the end of the year and hope to bring some US study sites on board before year end
Read more at https://stockhouse.com/news/press-releases/2019/10/07/london-health-sciences-centre-launches-as-newest-clinical-study-site-for-phase#RsQCy11hvL8zDUcJ.99
By the end of the year\Before tear end
Sounds like we should expect many NRs before ringing in the New Year
GO USA SITES GO
GO USA TREATMENTS GO